|
1
|
Kim JS, Kim JW, Han J, Shim YM, Park J and
Kim DH: Cohypermethylation of p16 and FHIT promoters as a
prognostic factor of recurrence in surgically resected stage I
non-small cell lung cancer. Cancer Res. 66:4049–4054. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Esteller M: Epigenetics provides a new
generation of oncogenes and tumour-suppressor genes. Br J Cancer.
94:179–183. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamada Y, Jackson-Grusby L, Linhart H,
Meissner A, Eden A, Lin H and Jaenisch R: Opposing effects of DNA
hypomethylation on intestinal and liver carcinogenesis. Proc Natl
Acad Sci USA. 102:13580–13585. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carraway H and Herman J: Montoring
methylation changes in caner. Methods Mol Biol. 383:187–202.
2007.
|
|
5
|
Chim CS, Liang R, Leung MH and Kwong YL:
Aberrant gene methylation implicated in the progression of
monoclonal gammopathy of undetermined significance to multiple
myeloma. J Clin Pathol. 60:104–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Durst KL and Hiebert SW: Role of RUNX
family members in transcriptional repression and gene silencing.
Oncogene. 23:4220–4224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Levanon D, Negreanu V, Bernstein Y, Bar-Am
I, Avivi L and Groner Y: AML1, AML2, and AML3, the human members of
the runt domain gene-family: cDNA structure, expression, and
chromosomal localization. Genomics. 23:425–432. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ito Y: Molecular basis of tissue-specific
gene expression mediated by the runt domain transcription factor
PEBP2/CBF. Genes Cells. 4:685–696. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bae SC and Choi JK: Tumor suppressor
activity of RUNX3. Oncogene. 23:4336–4340. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyazono K, Suzuki H and Imamura T:
Regulation of TGF-beta signaling and its roles in progression of
tumors. Cancer Sci. 94:230–234. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blyth K, Cameron ER and Neil JC: The RUNX
genes: gain or loss of function in cancer. Nat Rev Cancer.
5:376–387. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang Y, Tong D, Lou G, Zhang Y and Geng
J: Expression of RUNX3 gene, methylation status and
clinicopathological significance in breast cancer and breast cancer
cell lines. Pathobiology. 75:244–251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC and
Kim WJ: Methylation of the RUNX3 promoter as a potential prognostic
marker for bladder tumor. J Urol. 180:1141–1145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nomoto S, Kinoshita T, Mori T, Kato K,
Sugimoto H, Kanazumi N, Takeda S and Nakao A: Adverse prognosis of
epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic
cancer. Br J Cancer. 98:1690–1695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Waki T, Tamura G, Sato M, Terashima M,
Nishizuka S and Motoyama T: Promoter methylation status of
DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric
epithelia. Cancer Sci. 94:360–364. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Friedrich MJ, Rad R, Langer R, Voland P,
Hoefler H, Schmid RM, Prinz C and Gerhard M: Lack of RUNX3
regulation in human gastric cancer. J Pathol. 210:141–146. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tan SH, Ida H, Lau QC, Goh BC, Chieng WS,
Loh M and Ito Y: Detection of promoter hypermethylation in serum
samples of cancer patients by methylation-specific polymerase chain
reaction for tumour suppressor genes including RUNX3. Oncol
Rep. 18:1225–1230. 2007.
|
|
18
|
Sato K, Tomizawa Y, Iijima H, Saito R,
Ishizuka T, Nakajima T and Mori M: Epigenetic inactivation of the
RUNX3 gene in lung cancer. Oncol Rep. 15:129–135. 2006.
|
|
19
|
Yanagawa N, Tamura G, Oizumi H, Kanauchi
N, Endoh M, Sadahiro M and Motoyama T: Promoter hypermethylation of
RASSF1A and RUNX3 genes as an independent prognostic prediction
marker in surgically resected non-small cell lung cancers. Lung
Cancer. 5:131–138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yanagawa N, Tamura G, Oizumi H, et al:
Promoter hypermethylation of tumor suppressor and tumor-related
genes in non-small cell lung cancers. Cancer Sci. 94:589–592. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li QL, Kim HR, Kim WJ, Choi JK, Lee YH,
Kim HM, Li LS, Kim H, Chang J, Ito Y, Youl Lee K and Bae SC:
Transcriptional silencing of the RUNX3 gene by CpG hypermethylation
is associated with lung cancer. Biochem Biophys Res Commun.
314:223–228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herranz M and Esteller M: DNA methylation
and histone modifications in patients with cancer: potential
prognostic and therapeutic targets. Methods Mol Biol. 361:25–62.
2007.PubMed/NCBI
|
|
23
|
Fojtova M, Piskala A, Votruba I, Otmar M,
Bartova E and Kovarik A: Efficacy of DNA hypomethylating capacities
of 5-aza-2′-deoxycytidine and its alpha anomer. Pharmacol Res.
55:16–22. 2007.PubMed/NCBI
|
